Email Alert RSS
Volume 14 Issue 6
Nov.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
WU Haiting, LI Hang. ANCA Associated Vasculitis Treated with Ultra-low Dose Rituximab: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1330-1334. DOI: 10.12290/xhyxzz.2023-0263
Citation: WU Haiting, LI Hang. ANCA Associated Vasculitis Treated with Ultra-low Dose Rituximab: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1330-1334. DOI: 10.12290/xhyxzz.2023-0263
shu

ANCA Associated Vasculitis Treated with Ultra-low Dose Rituximab: A Case Report

  • Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-A-170

More Information
  • Corresponding author:

    WU Haiting, E-mail: wuhaiting03@163.com

  • Received Date: May 30, 2023
  • Accepted Date: July 17, 2023
  • Issue Publish Date: November 29, 2023
    Graphical Abstract
    • Abstract
  • We reported a case of ANCA-associated vasculitis with pulmonary and renal involvement that was effectively treated with glucocorticoids, cyclophosphamide, and plasma exchange therapy. The patient suffered two infections during maintenance treatment with azathioprine and was later switched to ultralow-dose (100 mg) rituximab to keep the disease in remission. Individualized rituximab therapy is effective in treating ANCA-associated vasculitis, while avoiding excessive immunosuppression, and reducing the financial burden. The diagnosis and treatment of this patient may help clinicians improve their understanding of maintenance therapy for ANCA-associated vasculitis.
    • FullText(HTML)
    • References (17)
  • [1]
    Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis[J]. Arthritis Rheumatol, 2022, 74: 400-406. DOI: 10.1002/art.41983
    [2]
    Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis[J]. J Am Soc Nephrol, 2010, 21: 1628-1636. DOI: 10.1681/ASN.2010050477
    [3]
    Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021, 100: 753-779. DOI: 10.1016/j.kint.2021.05.015
    [4]
    Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis[J]. N Engl J Med, 2010, 363: 221-232. DOI: 10.1056/NEJMoa0909905
    [5]
    Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis (RITUXVAS)[J]. N Engl J Med, 2010, 363: 211-220. DOI: 10.1056/NEJMoa0909169
    [6]
    Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis[J]. N Engl J Med, 2014, 371: 1771-1780. DOI: 10.1056/NEJMoa1404231
    [7]
    Sanderson J, Ansari A, Marinaki T, et al. Thiopurine methyltransferase: should it be measured before commencing thiopur-ine drug therapy[J]. Ann Clin Biochem, 2004, 41: 294-302. DOI: 10.1258/0004563041201455
    [8]
    Tieu J, Smith R, Basu N. et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines[J]. Rheumatology (Oxford), 2020, 59: e24-e32. DOI: 10.1093/rheumatology/kez640
    [9]
    Goel R, Morgan M, Chanouzas D, et al. Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis[J]. Rheumatol Adv Pract, 2021, 5: rkab039. DOI: 10.1093/rap/rkab039
    [10]
    Moiseev SV, Bulanov NM, Zykova AS, et al. Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy[J]. Ann Rheum Dis, 2019, 78: e99. DOI: 10.1136/annrheumdis-2018-213873
    [11]
    Schoergenhofer C, Schwameis M, Firbas C, et al. Single, very low rituximab doses in healthy volunteers—a pilot and a randomized trial: implications for dosing and biosimilarity testing[J]. Sci Rep, 2018, 9: 124.
    [12]
    Charles P, Terrier B, Perrodeau E, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase Ⅲ trial (MAINRITSAN2)[J]. Ann Rheum Dis, 2018, 77: 1143-1149. DOI: 10.1136/annrheumdis-2017-212878
    [13]
    Van Dam LS, Oskam JM, Kamerling SWA, et al. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients[J]. Front Immunol, 2020, 11: 566732. DOI: 10.3389/fimmu.2020.566732
    [14]
    Charles P, Perrodeau É, Samson M, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial[J]. Ann Intern Med, 2020, 173: 179-187. DOI: 10.7326/M19-3827
    [15]
    Merkel PA, Niles JL, Mertz LE, et al. Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis and in Microscopic Polyangiitis[J]. Arthritis Care Res (Hoboken), 2021, 73: 1372-1378. DOI: 10.1002/acr.24332
    [16]
    Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study[J]. Lancet Rheumatol, 2022, 4: e177-e187. DOI: 10.1016/S2665-9913(21)00394-5
    [17]
    Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-10 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative[J]. Lancet Rheumatol, 2022, 4: e33-e41. DOI: 10.1016/S2665-9913(21)00325-8
    • Related Articles

  • Related Articles

    [1]JIA Chunyu, WANG Gangan, WANG Jiahui, CHEN Gang, ZHENG Ke, LI Xuemei. Correlation Between Neutrophil to Lymphocyte Ratio and eGFR in Diabetic Patients: A Cross-sectional Analysis Based on NHANES Data[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 379-385. DOI: 10.12290/xhyxzz.2024-0908
    [2]WEN Bei, ZHU He, XU Li, HUANG Yuguang. Association Between Coffee Consumption and Pain: A Cross-sectional Study Based on American National Health and Nutrition Examination Survey[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 351-358. DOI: 10.12290/xhyxzz.2023-0553
    [3]LI Wendao, GU Hao, WANG Wei, WU Runhui, SONG Hongmei. First Case Report of FOXN1 Haploinsufficiency in China and Literature Review[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 366-372. DOI: 10.12290/xhyxzz.2022-0040
    [4]LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271
    [6]Ming-sheng MA, Xü-de ZHANG, Min WEI, Shi-min ZHAO, Zheng-qing QIU. Efficacy of Low Dose Corticosteroid Therapy in Duchenne Muscular Dystrophy[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 384-388. DOI: 10.3969/j.issn.1674-9081.2014.04.006
    [7]Qing-jun WU, Zhang-han DAI, Wen ZHANG, Yong-zhe LI, Xin-ping TIAN, Xuan ZHANG, Yan ZHAO, Xiao-feng ZENG, Feng-chun ZHANG, Fu-lin TANG. Characteristics of Antisynthetase Syndrome with Anti-threonyl tRNA Synthetase Antibody[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(1): 26-30. DOI: 10.3969/j.issn.1674-9081.2013.01.006
    [8]Ya-gang ZUO, Hong-wei WANG, Jia-bi WANG. Dual-wavelength Laser with 595 nm and 1064 nm Combination for Resistant Port-wine Stains[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 386-389. DOI: 10.3969/j.issn.1674-9081.2012.04.005
    [9]Jie LIU, Yue-ping ZENG, Chun-xia HE, Qin LONG, Hong-zhong JIN, Qiu-ning SUN. Corticosteroids plus Intravenous Immunoglobulin in the Treatment of 7 Cases with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 381-385. DOI: 10.3969/j.issn.1674-9081.2012.04.004
    [10]Shuai TANG, Jie YI, Yu-guang HUANG. Cardiovascular Responses of Intubation with Shikani Seeing Optical Stylet and Macintosh Laryngoscope[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(3): 314-317. DOI: 10.3969/j.issn.1674-9081.2012.03.015

  • Cited by

    Periodical cited type(0)

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (471) PDF downloads (87) Cited by(1)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close